FDA Inspection 1323036 — Priovant Therapeutics Inc.
The FDA completed an inspection of Priovant Therapeutics Inc. on May 1, 2026 in Durham, NC. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- May 1, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Durham, NC (United States)
Additional Details
Sponsor, Contract Research Organization